News & Media

Press Releases

Amolyt Pharma Announces Positive Data from Phase 1 Trial of AZP-3601 at the American Society for Bone and Mineral Research 2021 Annual Meeting

October 1, 2021

Download a PDF copy of this press release: EN FR Company to host key opinion leader webinar today, October 1, at 10:00am ET LYON, France, …

Download a PDF: EN or FR

Amolyt Pharma to Present Phase 1 Clinical Trial Data for Lead Product Candidate AZP-3601 at the American Society for Bone and Mineral Research 2021 Annual Meeting

September 21, 2021

Amolyt Pharma to Present Phase 1 Clinical Trial Data for Lead Product Candidate AZP-3601 at the American Society for Bone and Mineral Research 2021 Annual …

Download a PDF: EN or FR

Amolyt Pharma Announces $80 Million Series B Financing led by Sectoral Asset Management and Andera Partners

September 16, 2021

Download a PDF copy of this press release: EN FR Funds to be used to continue clinical development of AZP-3601 for hypoparathyroidism while progressing AZP-3813 …

Download a PDF: EN or FR

Presentations

AZP-3601

Healthcare Resource Utilization Burden of Patients with Hypoparathyroidism in the United States

Written by

walid

AZP-3601

KOL Webinar on AZP-3601 Featuring John P. Bilezikian, M.D., Ph.D.

Written by

Olivia

AZP-3601

Clinical Burden of Patients with Hypoparathyroidism in the United States: A Claims Data Analysis. ASMBR 2021.

Written by

walid

AZP-3601

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics following Single and Multiple Administration of AZP-3601, a Novel Long-Acting PTH Analog, to Healthy Adults. ASMBR 2021.

Written by

walid

AZP-3404

Improved Glucose Metabolism and Decreased Weight Gain in Leptin-Resistant, IGFBP2-Deficient, db/db Mice Induced by AZP-3404, a 9-Amino Acid Analog of IGFBP2. e-ECE 2021.

Written by

jpoly4

AZP-3601

Safety, Tolerability and Pharmacodynamics of AZP-3601, a Novel Long-Acting PTH Analog, in Healthy Adults: Data From a Randomized, Double-Blind, Placebo-Controlled Phase 1 Study. e-ECE 2021.

Written by

jpoly4

AZP-3601

cHP Natural History Study: ISPOR Poster

Written by

jpoly4

AZP-3404

AZP-3404, a Peptide Analog of IGFBP-2, Induces Weight Loss and Improves Glucose Metabolism in Leptin-Resistant db/db Mice. ENDO 2021.

Written by

jpoly4

AZP-3601

A Single Administration of AZP-3601, a Novel, Long-Acting PTH Analog, Induces a Significant and Sustained Calcemic Response: Preliminary Data From a Randomized, Double-Blind, Placebo-Controlled Phase 1 Study. ENDO 2021.

Written by

jpoly4

AZP-3601

Clinical Burden and Practice Patterns in Patients With Chronic Hypoparathyroidism in the United States (US): A Claims Data Analysis Using Diagnosis Based Criteria. ENDO 2021.

Written by

jpoly4

AZP-3601

Clinical Burden and Practice Patterns in Patients With Chronic Hypoparathyroidism in the United States (US): A Claims Data Analysis Using Surgery Based Criteria. ENDO 2021.

Written by

jpoly4

Upcoming events

J.P. Morgan 40th Annual Healthcare Conference

Date: January 10-13, 2022 (San Francisco, CA.)

Rare Disease Day

Date: February 28, 2022

European Congress of Endocrinology

Date: May 21 - May 24, 2022 (Milan, Italy)

Hypopara Awareness Day

Date: June 1, 2022

ENDO 2022 – Annual Meeting of the Endocrine Society

Date: June 10 – June 14, 2022 (Atlanta, Georgia)

ASBMR 2022 Annual Meeting

Date: September 9 - 12, 2022 (Austin, TX)

News & Media

Press Releases

Amolyt Pharma Announces Positive Data from Phase 1 Trial of AZP-3601 at the American Society for Bone and Mineral Research 2021 Annual Meeting

Amolyt Pharma to Present Phase 1 Clinical Trial Data for Lead Product Candidate AZP-3601 at the American Society for Bone and Mineral Research 2021 Annual Meeting

Amolyt Pharma Announces $80 Million Series B Financing led by Sectoral Asset Management and Andera Partners

Presentations

Healthcare Resource Utilization Burden of Patients with Hypoparathyroidism in the United States

KOL Webinar on AZP-3601 Featuring John P. Bilezikian, M.D., Ph.D.

Clinical Burden of Patients with Hypoparathyroidism in the United States: A Claims Data Analysis. ASMBR 2021.

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics following Single and Multiple Administration of AZP-3601, a Novel Long-Acting PTH Analog, to Healthy Adults. ASMBR 2021.

Improved Glucose Metabolism and Decreased Weight Gain in Leptin-Resistant, IGFBP2-Deficient, db/db Mice Induced by AZP-3404, a 9-Amino Acid Analog of IGFBP2. e-ECE 2021.

Safety, Tolerability and Pharmacodynamics of AZP-3601, a Novel Long-Acting PTH Analog, in Healthy Adults: Data From a Randomized, Double-Blind, Placebo-Controlled Phase 1 Study. e-ECE 2021.

cHP Natural History Study: ISPOR Poster

AZP-3404, a Peptide Analog of IGFBP-2, Induces Weight Loss and Improves Glucose Metabolism in Leptin-Resistant db/db Mice. ENDO 2021.

A Single Administration of AZP-3601, a Novel, Long-Acting PTH Analog, Induces a Significant and Sustained Calcemic Response: Preliminary Data From a Randomized, Double-Blind, Placebo-Controlled Phase 1 Study. ENDO 2021.

Clinical Burden and Practice Patterns in Patients With Chronic Hypoparathyroidism in the United States (US): A Claims Data Analysis Using Diagnosis Based Criteria. ENDO 2021.

Clinical Burden and Practice Patterns in Patients With Chronic Hypoparathyroidism in the United States (US): A Claims Data Analysis Using Surgery Based Criteria. ENDO 2021.

Upcoming events

Social Updates

TWITTER